

Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab)

Catalog # APR11572

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P01375 & Q16552-1
Reactivity	Human
Clonality	Bispecific
Isotype	DVD-Ig

Additional Information


Target/Specificity	TNFSF2 / TNFa,IL-17 / IL-17A / CTLA-8
Expression system	CHO

Protein Information

Images




Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 100.00%, determined by SEC-HPLC.


Remtolumab bound to IL-17a protein, and then rebounded to secondary antibodies (human-IgG-Fc-HRP), and read OD450. As shown in fig, Remtolumab bound to huIL-17a-His, and the EC50 was 0.072 nM.




Remtolumab bound to TNFα protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Remtolumab bound to hu-TNFα-Fc , and the EC50 was 0.027 nM.



Remtolumab bound to huTNFα-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Remtolumab bound to huTNFα-CHO-K cells, and the EC50 was 148.700 nM.



Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Remtolumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Remtolumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 0.130 nM.



The detected weight of Anti-TNFα & IL-17 Reference Antibody (Remtolumab) is 198.49 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.